SCHOLAR ROCK HOLDING CORPORATION Operating Lease, Expense
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Operating Lease, Expense of $7.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2025-02-27
- SCHOLAR ROCK HOLDING CORPORATION operating lease, expense for fiscal 2024 was $7.00M, a 15.66% decline from fiscal 2023.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, expense for fiscal 2023 was $8.30M, a 4.60% decline from fiscal 2022.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, expense for fiscal 2022 was $8.70M, a 1.16% increase from fiscal 2021.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, expense for fiscal 2021 was $8.60M, a 168.75% increase from fiscal 2020.
| Period end | Operating Lease, Expense 12 month |
|---|---|
| 2024-12-31 | $7.00M 10-K · filed 2025-02-27 |
| 2023-12-31 | $8.30M 10-K · filed 2025-02-27 |
| 2022-12-31 | $8.70M 10-K · filed 2024-03-19 |
| 2021-12-31 | $8.60M 10-K · filed 2023-03-07 |
| 2020-12-31 | $3.20M 10-K · filed 2022-03-07 |
| 2019-12-31 | $1.40M 10-K · filed 2021-03-09 |
| 2018-12-31 | $1.00M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |